Accidental extravasation of anthracycline-based chemotherapy is a complication that has been feared since the introduction of the anthracyclines more than 40 years ago. Tissue infiltration with vesicant drugs may lead to progressive necrosis and destruction of muscles, tendons, nerves, and joints, and may be associated with severe functional and cosmetic changes. During the last four decades, much effort has been made to prevent such accidents from happening. In addition, different surgical approaches and several non-pharmacolgical and pharmacological treatments have been used to counteract the devastating effects of the extravasation. Most treatment modalities have been empirically based, and only a few have undergone thorough evaluation. Recently, dexrazoxane was shown to be an effective and non-toxic acute treatment for anthracycline extravasation. It has since become a widely recommended treatment, and Totect ® is currently the only approved drug for this indication.
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For 40 years, the use of anthracycline anticancer drugs has been a mainstay in the curative and palliative treatment of many solid tumors and hematological malignancies. Millions of patients have received treatment with doxorubicin, epirubicin, daunorubicin, and several newer analogs. Regrettably, a small fraction of patients have suffered from the unintentional extravasation of these drugs, which is a potentially devastating complication.
After the unintended leakage into the peri-vascular tissues, the clinical course is characterized by redness and swelling. Pain may be present, but is not mandatory for diagnosis. Within days to weeks, blisters, ulceration, and necrosis may occur, and the tissue destruction may continue into adjacent areas. Anthracyclines have a propensity to persist in tissues for months.
1,2 Accordingly, the progressive tissue destruction may continue for weeks and even months.
The tendency to form necrosis and ulceration depends in part on the amount and concentration of the anthracycline. Other factors that may play a role are host factors such as the location and venous flow. Not all anthracycline extravasations develop into ulceration. However, for significant extravasations the risk is estimated to be 25-50%. [3] [4] [5] [6] [7] [8] Unless treated, the complication may cause short-term defects, infections, and discontinuation of the scheduled antineoplastic treatment, as well as long-term cosmetic and functional defects.
7,9,10
Prevention
Following the initial descriptions in the 1970s of progressive ulceration and destruction of deeper neurovascular or tendon structures, it became clear that every precaution should be taken to prevent extravasations. 11, 12 Intense surveillance by the treating nurse during anthracycline infusion has since then been routinely carried out in most oncology institutions. 13 Other preventive measures include the use of central venous access devices that may reduce the risk for extravasation; however, this does not completely eliminate the risk.
Surgical Treatment
There are no uniform guidelines for the surgical treatment of anthracycline extravasations. It has generally been agreed that for Saline-flushing of the infiltrated tissue through multiple incisions is a surgical technique that has been adopted by some institutions. 17, 18 However, it is time-consuming, and will not remove all of the extravasated anthracycline. No biopsy-verified studies have been conducted to demonstrate its efficacy.
In our experience, the incidence of surgical anthracycline treatment diminishes dramatically with the introduction of dexrazoxane (Savene ® in Europe and Totect ® in the US). We outline evidence from experimental studies and clinical use in the paragraphs below.
Non-surgical Treatment
The list of non-surgical, mostly local, treatment modalities that have been used experimentally against anthracycline extravasation injuries is very long. Some of the most clinically used managements are cooling, 4, 9, 19, 20 topical dimethyl sulfoxide (DMSO), [21] [22] [23] [24] [25] [26] [27] [28] topical and intralesional hyaluronidase, 29 or corticosteroids. 3, [30] [31] [32] The rationale for using these treatments ranges from free radical scavenging, changing of skin permeability, and enhanced anthracycline absorption to antiinflammatory treatment, but from both a clinical and pre-clinical perspective, the documentation is poor.
Experimental Studies with Dexrazoxane
A turning point in the treatment of anthracycline extravasation emerged with the discovery that the bisdioxopiperazine dexrazoxane had a hitherto unseen high efficacy in preventing experimentally induced anthracycline ulcers. The background for these experiments was the recognition that dexrazoxane is a catalytic inhibitor of DNA topoisomerase II and, additionally, acts as a strong metal ion chelator that is able to remove iron from the iron-anthracycline complex, as well as preventing the formation of reactive oxygen species. 33, 34 The exact mechanism of action in which dexrazoxane acts as an antidote in tissue extravasation injuries has not yet been identified.
In a large number of animal experiments, not only was it possible to demonstrate a highly significant reduction in both frequency and size of ulcers, but also complete prevention of anthracyclineinduced ulcers was achieved with repeated doses of systemic dexrazoxane. 35, 36 It was noted that delayed treatment was also associated with somewhat reduced efficacy. 37 Finally, it was shown that topical DMSO actually had a tendency to decrease the efficacy of dexrazoxane.
Clinical Experience with Dexrazoxane
The experimental results were soon translated into pilot clinical use.
First, we briefly described the successful dexrazoxane treatment of two patients with large anthracycline extravasations; one patient had a biopsy-proven epirubicin extravasation of her forearm, while the other had a large chest wall doxorubicin extravasation from a central catheter. 38 No surgical intervention became necessary, and no sequelae were observed. Several subsequent case reports confirmed the feasibility of the treatment. 
